Brief: Bausch Health Companies - FDA Approves Cabtreo(Tm) Topical Gel For Treatment Of Acne Vulgaris In Patients Twelve Years Of Age And Older
20/10/2023 22:31
Oct 20 (Reuters) - Bausch Health Companies Inc BHC.TO :
* BAUSCH HEALTH COMPANIES - FDA APPROVES CABTREO(TM) TOPICAL
GEL
FOR TREATMENT OF ACNE VULGARIS IN PATIENTS TWELVE YEARS OF AGE
AND OLDER
* BAUSCH HEALTH COMPANIES INC - CABTREO IS EXPECTED TO BE
AVAILABLE TO PATIENTS IN Q1 2024
Source text for Eikon: ID:
Further company coverage: BHC.TO
Recent news on Bausch Health Companies
See all newsBausch + Lomb CEO Saunders departs, Chairman Appio named interim chief (updated)
Brief: Bausch + Lomb And Bausch Health Announce Appointment Of Thomas J. Appio As Interim Bausch + Lomb CEO, Expect To Raise Full-Year 2026 Guidance
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief
Brief: Bausch Health Companies -Co And Yun Expand Strategic Collaboration In Mexico And EMEA Markets
Canada Stocks: Toronto stocks near record high as investors weigh earnings, US PPI data